Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31533165 | 1.00 | MEN1 (0.34) | MEN1KMT2AGAAPIN1ABL1 | |
| SCHEMBL2393577 | 0.81 | RXRA (0.38) | PIN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2966721 | 0.79 | CDK1 (0.42) | MEN1KMT2AGAAPIN1ABL1 | |
| SCHEMBL19906958 | 0.79 | MEN1 (0.33) | MEN1KMT2AGAAPIN1ABL1 | |
| SCHEMBL20101541 | 0.79 | ALDH1A1 (0.42) | MEN1KMT2AGAAPIN1KDM4E | |
| SCHEMBL13649024 | 0.78 | MEN1 (0.35) | MEN1KMT2AGAAPIN1ABL1 | |
| SCHEMBL20101542 | 0.76 | PIN1 (0.51) | GAAPIN1KDM4E | |
| SCHEMBL22400986 | 0.76 | CA12 (0.35) | MEN1KMT2AGAA | |
| SCHEMBL31533157 | 0.75 | LMNA (0.36) | MEN1KMT2AGAAPIN1ALDH1A1 | |
| SCHEMBL16318669 | 0.75 | CDK1 (0.35) | MEN1KMT2AGAAABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988373-B2 | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20180118694-A1 | 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118694-A1 | 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S | MEN1 382/4885KMT2A 957/4885GAA 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.